David Lorente1, Karim Fizazi2, Christopher Sweeney3, Johann S de Bono4. 1. Medical Oncology Department, Hospital Universitario La Fe, Valencia, Spain. 2. Institut Gustave Roussy, University of Paris Sud, Villejuif, France. 3. Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA, USA. 4. Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Electronic address: johann.de-Bono@icr.ac.uk.
Abstract
CONTEXT: Unprecedented development of therapeutics for prostate cancer in recent years has left clinicians with the challenge of adequately sequencing therapeutic agents to optimise patient benefit. No clear guidelines exist on optimal treatment sequences. OBJECTIVE: To summarise the evidence on first-line activity, cross-resistance, and potential combinations of agents approved for metastatic castration-resistant prostate cancer (mCRPC). EVIDENCE ACQUISITION: A nonsystematic literature search of articles on agent sequencing in mCRPC in PubMed and relevant cancer conferences up to June 2016 was performed. EVIDENCE SYNTHESIS: No definitive evidence on the optimal mCRPC treatment sequence exists. Hormonal agents are preferred for first-line treatment on the basis of favourable toxicity, but no evidence of superiority over chemotherapy exists. Evidence suggests significant cross-resistance between agents in first- and second-line settings. The impact of prior chemotherapy in metastatic hormone-sensitive disease is unknown. No combinations have proven benefit to date. Molecular biomarker assessment in liquid biopsies may aid selection of treatment in the near future. CONCLUSIONS: It is unlikely that a single sequence will be adequate for all mCRPC patients. An individualised strategy that assesses the biological mechanisms of the disease and monitors molecular drivers of progression and resistance to treatment is required to maximise benefit for each patient and bring us closer to the goal of best care. PATIENT SUMMARY: In this review we summarise evidence on the optimal sequence of anticancer drugs for metastatic castration-resistant prostate cancer. No agent has proven superior to another as front-line treatment, and the exact impact of prior treatments on drug efficacy is unknown. Better biomarkers for treatment selection and evaluation of response to treatment will be needed to personalise the optimal sequence for each individual patient.
CONTEXT: Unprecedented development of therapeutics for prostate cancer in recent years has left clinicians with the challenge of adequately sequencing therapeutic agents to optimise patient benefit. No clear guidelines exist on optimal treatment sequences. OBJECTIVE: To summarise the evidence on first-line activity, cross-resistance, and potential combinations of agents approved for metastatic castration-resistant prostate cancer (mCRPC). EVIDENCE ACQUISITION: A nonsystematic literature search of articles on agent sequencing in mCRPC in PubMed and relevant cancer conferences up to June 2016 was performed. EVIDENCE SYNTHESIS: No definitive evidence on the optimal mCRPC treatment sequence exists. Hormonal agents are preferred for first-line treatment on the basis of favourable toxicity, but no evidence of superiority over chemotherapy exists. Evidence suggests significant cross-resistance between agents in first- and second-line settings. The impact of prior chemotherapy in metastatic hormone-sensitive disease is unknown. No combinations have proven benefit to date. Molecular biomarker assessment in liquid biopsies may aid selection of treatment in the near future. CONCLUSIONS: It is unlikely that a single sequence will be adequate for all mCRPC patients. An individualised strategy that assesses the biological mechanisms of the disease and monitors molecular drivers of progression and resistance to treatment is required to maximise benefit for each patient and bring us closer to the goal of best care. PATIENT SUMMARY: In this review we summarise evidence on the optimal sequence of anticancer drugs for metastatic castration-resistant prostate cancer. No agent has proven superior to another as front-line treatment, and the exact impact of prior treatments on drug efficacy is unknown. Better biomarkers for treatment selection and evaluation of response to treatment will be needed to personalise the optimal sequence for each individual patient.
Authors: Sofia España; Maria Ochoa de Olza; Nuria Sala; Josep Maria Piulats; Ulises Ferrandiz; Olatz Etxaniz; Lucia Heras; Oscar Buisan; Juan Carlos Pardo; Jose F Suarez; Pilar Barretina; Josep Comet; Xavier Garcia Del Muro; Lauro Sumoy; Albert Font Journal: Cancer Manag Res Date: 2020-10-16 Impact factor: 3.989
Authors: K Kobayashi; N Okuno; G Arai; H Nakatsu; A Maniwa; N Kamiya; T Satoh; H Kikukawa; Y Nasu; H Uemura; T Nakashima; K Mikami; M Iinuma; K Tanabe; J Furukawa; H Kobayashi Journal: Jpn J Clin Oncol Date: 2021-04-01 Impact factor: 3.019
Authors: Neal Shore; Celestia S Higano; Daniel J George; Cora N Sternberg; Fred Saad; Bertrand Tombal; Kurt Miller; Jan Kalinovsky; XiaoLong Jiao; Krishna Tangirala; Oliver Sartor Journal: Prostate Cancer Prostatic Dis Date: 2020-05-13 Impact factor: 5.455
Authors: Neal D Shore; François Laliberté; Raluca Ionescu-Ittu; Lingfeng Yang; Malena Mahendran; Dominique Lejeune; Louise H Yu; Joseph Burgents; Mei Sheng Duh; Sameer R Ghate Journal: Adv Ther Date: 2021-07-19 Impact factor: 3.845